137 related articles for article (PubMed ID: 26225264)
1. Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Foster D; Upton RN
CPT Pharmacometrics Syst Pharmacol; 2015 Jun; 4(6):362-71. PubMed ID: 26225264
[TBL] [Abstract][Full Text] [Related]
2. A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
Yao X; Wu Y; Jiang J; Chen X; Liu D; Hu P
Eur J Pharm Sci; 2019 Aug; 136():104942. PubMed ID: 31154006
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
4. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
5. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Bae J; Park JW
Drug Dev Ind Pharm; 2016; 42(2):254-62. PubMed ID: 26006334
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis?
Rawdha T; Aicha BT; Lobna BA; Issam S; Mouna BS; Olfa S; Selma B; Takoua BB; Kawther BA; Leila M; Hana S; Ines M; Leila A
Drug Metab Pers Ther; 2023 Mar; 38(1):79-85. PubMed ID: 35998916
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.
Russo PA; Wiese MD; Smith MD; Ahern MJ; Barbara JA; Shanahan EM
Ann Pharmacother; 2013 Mar; 47(3):e15. PubMed ID: 23447478
[TBL] [Abstract][Full Text] [Related]
8. Chronic Diarrhea Associated with High Teriflunomide Blood Concentration.
Duquette A; Frenette AJ; Doré M
Rheumatol Ther; 2016 Jun; 3(1):179-185. PubMed ID: 27747512
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS.
Rakhila H; Rozek T; Hopkins A; Proudman S; Cleland L; James M; Wiese M
J Pharm Biomed Anal; 2011 May; 55(2):325-31. PubMed ID: 21349677
[TBL] [Abstract][Full Text] [Related]
10. Individualization of leflunomide dosing in rheumatoid arthritis patients.
Hopkins AM; O'Doherty CE; Foster DJ; Upton RN; Proudman SM; Wiese MD
Per Med; 2014 Jun; 11(4):449-461. PubMed ID: 29783485
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
12. Development of a population pharmacokinetic model and optimal dosing regimen of leflunomide in Korean population.
Shin Y; Chae D; Park K
Eur J Pharm Sci; 2023 May; 184():106402. PubMed ID: 36754259
[TBL] [Abstract][Full Text] [Related]
13. Painful Small Fiber Neuropathy Associated With Teriflunomide: A Case Series and Literature Review Related to Teriflunomide and Leflunomide.
Elrefaey A; Memon AB
Cureus; 2023 Sep; 15(9):e45079. PubMed ID: 37705563
[TBL] [Abstract][Full Text] [Related]
14. On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.
Kujawski J; Bernard MK; Jodłowska E; Czaja K; Drabińska B
J Mol Model; 2015 May; 21(5):105. PubMed ID: 25851105
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
Ma LL; Wu ZT; Wang L; Zhang XF; Wang J; Chen C; Ni X; Lin YF; Cao YY; Luan Y; Pan GY
Acta Pharmacol Sin; 2016 Mar; 37(3):415-24. PubMed ID: 26806301
[TBL] [Abstract][Full Text] [Related]
16. Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration.
Hopkins AM; Moghaddami M; Foster DJ; Proudman SM; Upton RN; Wiese MD
Drug Metab Dispos; 2017 Jan; 45(1):8-16. PubMed ID: 27742727
[TBL] [Abstract][Full Text] [Related]
17. Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.
Palmer AM
Curr Opin Investig Drugs; 2010 Nov; 11(11):1313-23. PubMed ID: 21157651
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of leflunomide in rheumatoid arthritis.
Keen HI; Conaghan PG; Tett SE
Expert Opin Drug Saf; 2013 Jul; 12(4):581-8. PubMed ID: 23668332
[TBL] [Abstract][Full Text] [Related]
19. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
[TBL] [Abstract][Full Text] [Related]
20. Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Prescrire Int; 2015 Mar; 24(158):61-4. PubMed ID: 25897452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
